Abstract
Report Details
Stem cell technologies - changes to US regulations to give exciting new
hopes and potentially vast commercial opportunities - brand new indepth study
Stem cells represent one of the most promising medical breakthroughs of all
time, as our new market report explains. Currently, in 2009, the new US
administration is lifting some major restrictions on stem cells technologies.
This developmental obstacle now removed, all types of stem cells are available
for expanding the therapeutic and commercial potentials, as our new report
Stem Cells - The Hype & Hope - World Analysis 2009-2024 explains. Based
upon the cells that create and renew all tissues potentially, stem cell
therapies could revolutionise the treatment of disease, especially through
tissue and organ replacement. Stem cells could provide revolutionary
treatments for conditions from diabetes to multiple sclerosis, and from
myocardial infarction to chronic obstructive pulmonary disease, amongst many
others. Stem cell lines could also change the way pharmaceutical companies
assess new chemical entities during R&D.
A conservative estimate places the potential market value of stem cells at
over $150bn by late next decade. But will stem cell products be ready to meet
regulatory hurdles and market requirements? Where is stem cell research
heading today? What stem cell therapies are likely to hit the market from 2009
onwards? Where does the highest value lie in the short-term? What are the
commercial threats there? This new visiongain report answers these and other
crucial questions about this important developing field, one with vast
commercial potential.
Comprehensive analysis of the global stem cells sector and market Stem Cells
- The Hype & Hope - World Analysis 2009-2024 examines stem cells technology
critically. We used a comprehensive review of information sources, including
consultations with relevant experts. This report provides detailed sales
forecasts, discussions of pipeline developments and analyses of important
contemporary issues, especially relevant commercial drivers and restraints.
This report also covers regulations and ethics. Sources used include
commercial databases, industry news, published reports, policy documents and
economic research. Importantly, visiongain applied rigorous financial
forecasting, qualitative analyses and the assessment of unmet needs. The
result is a comprehensive market- and industry-centred report with detailed
analysis and informed opinion that you will not find elsewhere.
Why you should buy this report:
Key information that you will find in Stem Cells - The Hype & Hope - World Analysis 2009-2024 includes:
- Analyses of the existing market value for stem cells
- Analyses of the potential market value of stem cell therapies, including
detailed revenue forecasts from 2009 to 2024
- Forecasts for existing stem cell markets, including private cord blood
banks and Osiris Therapeutics and NuVasive' s Osteocel
- Discussions of ethical complications and situations that influence the way
stem cell medicine is perceived, researched and conducted
- Analyses of key organisations, suppliers and relevant national laws
- Expert opinions from original research interviews with key opinion leaders
in stem cells research and technology
- Informed analyses of the strengths and weaknesses of the technologies from
2009 onwards
- Balanced assessments of commercial drivers and restraints in the stem
cells field.
- Visiongain believes that stem cell technologies are progressing rapidly.
We predict that more products will enter the market over the coming 5 years,
changing the commercial landscape for stem cells.
| 
View Cart
